

Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes

M.S. Macauley, Y. He, T.M. Gloster, K.A. Stubbs, G.J. Davies, and D.J. Vocadlo*

*Correspondence: dvocadlo@sfu.ca

DOI 10.1016/j.chembiol.2010.10.006

(Chemistry & Biology 17, 937–948; September 24, 2010)

The following conflict of interest statement was inadvertently omitted from the final manuscript during the production process:

M.S.M., K.A.S., and D.J.V. are eligible to receive royalties from Simon Fraser University. G.J.D. is a member of the scientific advisory board of Alectos Therapeutics. D.J.V. is a founder, shareholder, consultant, and member of the scientific advisory board of Alectos Therapeutics.

Chemistry & Biology apologizes for this omission.

Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis

M.S. Macauley, X. Shan, S.A. Yuzwa, T.M. Gloster, and D.J. Vocadlo*

*Correspondence: dvocadlo@sfu.ca

DOI 10.1016/j.chembiol.2010.10.007

(Chemistry & Biology 17, 949–958; September 24, 2010)

The following conflict of interest statement was inadvertently omitted from the final manuscript during the production process:

M.S.M., X.S., S.A.Y., and D.J.V. are eligible to receive royalties from Simon Fraser University. D.J.V. is a founder, shareholder, consultant, and member of the scientific advisory board of Alectos Therapeutics.

Chemistry & Biology apologizes for this omission.